PDS Biotechnology Corporation (PDSB) Stock Analysis & Winston Score

Winston Score History

PDS Biotechnology is a small clinical-stage biotech company focused on developing cancer immunotherapy treatments. Its core technology, called Versamune, is a platform designed to train the immune system to recognize and attack cancer cells. The company is working on treatments for cancers like HPV-related head and neck cancer and cervical cancer, targeting patients who have limited options with existing therapies.

PDS Biotechnology does not yet sell any approved products, so it generates no product revenue. It funds its research primarily through equity offerings and grants, including support from the U.S. Department of Defense. The company operates mainly in the United States and is considered pre-revenue, which means it burns cash while running clinical trials. Its main competitive edge, if its platform works, would be the proprietary Versamune technology — but the biggest risk is that clinical trials could fail, which would leave the company without a path to revenue and dependent on continued outside funding.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+14.3% YoY

YoY Growth Rate

Steady EPS growth

Insider Activity

2.7%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

$6M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

PDS Biotechnology Corporation has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-874.7%

Weak — -874.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial